home / stock / inno:cc / inno:cc news

INNO:CC News and Press, Innocan Pharma Corporation - Common Shares From 10/13/22

Stock Information
Company Name: Innocan Pharma Corporation - Common Shares
Stock Symbol: INNO:CC
Market: CNQC
Website: innocanpharma.com
Menu
INNO:CC INNO:CC Quote INNO:CC Short INNO:CC News INNO:CC Articles INNO:CC Message Board
Get INNO:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
INNO:CC - Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) a pharmaceutical tech company focusing on developing innovative drug delivery platform technolo...
INNO:CC - Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabino...

INNO:CC - Innocan Pharma Provides an Operational Update

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 21, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabi...

INNO:CC - Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsy The dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT (CBD Loaded Liposome Platform), seizures stopped fo...
INNO:CC - Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabin...

INNO:CC - Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operatin...

INNO:CC - Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injection Pain and well-being scores improved following treatment Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) ...
INNO:CC - Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technology This is compared to 6.5-20% bioavailability in humans when administered orally Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corpor...

INNO:CC - Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", c...

INNO:CC - Innocan Pharma Files PCT Patent Application for Diabetic Symptoms

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of diabetic sympt...
Previous 10 Next 10